Literature DB >> 11039477

Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression.

X Z Ding1, D M Fehsenfeld, L O Murphy, J Permert, T E Adrian.   

Abstract

Pancreatic carcinoma is characterized by poor prognosis and lack of response to conventional therapy for reasons that are not clear. Because of the structural relationship between the exocrine and endocrine pancreas and high concentrations of islet hormones bathing pancreatic tissue, we hypothesized that pancreatic cancer cell proliferation and glucose utilization are regulated by pancreatic islet hormones, particularly insulin. Based on this, the effect of islet hormones on pancreatic cancer cells in vitro was investigated. Five pancreatic cancer cell lines, CD11, CD18, HPAF, PANC-1, and MiaPaCa2 were used to investigate the effect of islet hormones on cell proliferation, glucose utilization, and GLUT-1 expression. Insulin, but not somatostatin and glucagon, induced pancreatic cancer cell growth in a concentration- and time-dependent manner. At concentrations within the range of those in the intrapancreatic vasculature, insulin (10(-10)-10(-8) mol/L) markedly increased [3H]-thymidine incorporation. Insulin significantly enhanced glucose utilization of pancreatic cancer cells before it enhanced cell proliferation. The MAPK kinase inhibitor PD 098059 abolished insulin-stimulated DNA synthesis and partially reduced insulin-stimulated glucose uptake. In contrast, the PI3 kinase inhibitor wortmannin substantially inhibited insulin-induced glucose uptake and partially blocked thymidine incorporation. Furthermore, after 24-hour treatment with insulin, GLUT-I expression in pancreatic cancer cells was markedly increased, indicating that insulin enhances glucose utilization partly through increasing glucose transport. These findings suggest that insulin stimulates proliferation and glucose utilization in pancreatic cancer cells by two distinct pathways. Insulin augments DNA synthesis mainly by MAP kinase activation and glucose uptake mainly by PI3 kinase activation and enhancement of GLUT-I expression. High intrapancreatic concentrations of insulin are likely to play an important role in stimulating pancreatic cancer growth indirectly by increasing substrate availability as well as by direct action as a trophic factor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11039477     DOI: 10.1097/00006676-200010000-00014

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  41 in total

Review 1.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

2.  Diabetes and pancreatic cancer.

Authors:  Donghui Li
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

3.  LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice.

Authors:  Rene Hennig; Jacinthe Ventura; Ralf Segersvard; Erin Ward; Xian-Zhong Ding; Sambasiva M Rao; Borko D Jovanovic; Takeshi Iwamura; Mark S Talamonti; Richard H Bell; Thomas E Adrian
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

4.  Hypoxia inducible factor-1 mediates effects of insulin on pancreatic cancer cells and disturbs host energy homeostasis.

Authors:  Feng Wang; Shu Shun Li; Ralf Segersvärd; Lisa Strömmer; Karl-Gösta Sundqvist; Jan Holgersson; Johan Permert
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 5.  New insights into pancreatic cancer-induced paraneoplastic diabetes.

Authors:  Raghuwansh P Sah; Sajan Jiv Singh Nagpal; Debabrata Mukhopadhyay; Suresh T Chari
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-26       Impact factor: 46.802

6.  GLUT-1 expression in pancreatic neoplasia: implications in pathogenesis, diagnosis, and prognosis.

Authors:  Olca Basturk; Rajendra Singh; Ecmel Kaygusuz; Serdar Balci; Nevra Dursun; Nil Culhaci; N Volkan Adsay
Journal:  Pancreas       Date:  2011-03       Impact factor: 3.327

Review 7.  Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions.

Authors:  Claudio Vernieri; Stefano Casola; Marco Foiani; Filippo Pietrantonio; Filippo de Braud; Valter Longo
Journal:  Cancer Discov       Date:  2016-11-21       Impact factor: 39.397

8.  Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis.

Authors:  Claudio Vernieri; Fabio Galli; Laura Ferrari; Paolo Marchetti; Sara Lonardi; Evaristo Maiello; Rosario V Iaffaioli; Maria G Zampino; Alberto Zaniboni; Sabino De Placido; Maria Banzi; Azzurra Damiani; Daris Ferrari; Gerardo Rosati; Roberto F Labianca; Paolo Bidoli; Giovanni L Frassineti; Mario Nicolini; Lorenzo Pavesi; Maria C Tronconi; Angela Buonadonna; Sabrina Ferrario; Giovanni Lo Re; Vincenzo Adamo; Emiliano Tamburini; Mario Clerico; Paolo Giordani; Francesco Leonardi; Sandro Barni; Andrea Ciarlo; Luigi Cavanna; Stefania Gori; Saverio Cinieri; Marina Faedi; Massimo Aglietta; Maria Antista; Katia F Dotti; Francesca Galli; Maria Di Bartolomeo
Journal:  Oncologist       Date:  2019-01-03

Review 9.  Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection.

Authors:  Andrew E Becker; Yasmin G Hernandez; Harold Frucht; Aimee L Lucas
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

10.  Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium.

Authors:  C Bosetti; V Rosato; D Li; D Silverman; G M Petersen; P M Bracci; R E Neale; J Muscat; K Anderson; S Gallinger; S H Olson; A B Miller; H Bas Bueno-de-Mesquita; G Scelo; V Janout; I Holcatova; P Lagiou; D Serraino; E Lucenteforte; E Fabianova; P A Baghurst; W Zatonski; L Foretova; E Fontham; W R Bamlet; E A Holly; E Negri; M Hassan; A Prizment; M Cotterchio; S Cleary; R C Kurtz; P Maisonneuve; D Trichopoulos; J Polesel; E J Duell; P Boffetta; C La Vecchia; P Ghadirian
Journal:  Ann Oncol       Date:  2014-07-23       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.